Skip to content
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

BioLife Solutions Inc. BLFS

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$96.2M
▲ 28.9% YoY
$-4.6M
$10.6M
▲ 104.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

BioLife Solutions, Inc. is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. It currently operates as one bioproduction products and services business which supports several steps in the biologic material manufacturing and delivery process. Its bioproduction products and services are comprised of one revenue line that contains three main offerings: cell processing and other products, including biopreservation media, human platelet lysate media, cryogenic and ultralow temperature containers, and automated cell-processing fill machines; and automated thawing devices. It maintains and operates two independent cGMP clean room production suites for manufacturing sterile biopreservation media products in Bothell, Washington. It also maintains and operates one cGMP clean room production suite for manufacturing hPL media in Indianapolis, Indiana. As of December 31, 2025, it had 155 full-time team members and no part-time team members. The company was incorporated in Delaware in 1987 under the name Trans Time Medical Products, Inc. Following a later merger with its wholly owned subsidiary, it changed its name to BioLife Solutions, Inc.

Written from the business description in BIOLIFE SOLUTIONS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 96.2M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 96.2 · Net income -4.6
50M100M-50M-100M
201020132016201920222025
Compound annual growth
+8.1%
+14.9%
+31.0%
+29.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -17.3% · Net -4.8%
-50%-100%-150%
201020172025
ROE
FY2025 · ROE -1.3%
-50%-100%
201020172025
Three returns, three denominators.

Each USD of equity lost 1 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 10.6
5M10M-10M-20M
201020172025

Total assetsUSD 405.9M
EquityUSD 371.9M
CashUSD 33.0M
Gross debtUSD 5.0M
Net debtUSD -28.0M
Current ratio5.94×

The company holds more cash than debt.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BLFS, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.10.10.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.00.0−0.00.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.0◌0.00.00.00.00.00.0◌◌
Net income $B−0.0−0.0−0.1−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.0−0.0−0.0−0.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.10−0.44−1.55−3.25−0.23−0.06−0.09−1.56−0.21−0.54−0.35−0.31−0.22−0.33−0.03−0.03
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−1.3−5.9−19.4−33.2−2.61.6−5.7——−117.8−37.5—————
Shares out B0.050.050.000.040.040.030.020.020.010.010.010.010.010.070.070.07

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 75 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image